The world osteoporosis drugs market will reach $8.36BN in 2014

Monday 30 June 2014, Amsterdam

The new report, now available on ASDReports, calculates that the global osteoporosis drugs market will reach $8.36bn in 2014 with revenues showing strong growth to 2024. These revenue forecasts and others appear in the new 217 page report Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies.

According to the International Osteoporosis Foundation (IOF), it is estimated that over 200 million people worldwide suffer from this disease, where nearly 38% of these people are based in US, Europe and Japan. According to the WHO, approximately 1.66 million hip fractures occur each year worldwide, setting the incidence of osteoporosis to increase four-fold by 2050 due to the increasing ageing population.

The new report forecasts revenues in the world osteoporosis drug market will expand from 2014 to 2024. The average age to develop osteoporosis is increasing each year. As it does, the prevalence of osteoporosis and the demand for treatments that prevent fragility fracture will continue to rise. Ageing demographics will continue to stimulate demands for osteoporosis treatments that are easy to adhere to and enhance bone density.

The lead author of this report commented: “Osteoporosis represents a major public health concern. It is the most common bone disease in humans and is a silent disease, until it is complicated by fractures. To prevent fracture, osteoporotic treatments are prescribed to attempt increasing bone strength and density.

Osteoporosis forms an industry and market with immense potential. The number of people with osteoporosis worldwide will increase over the next ten years, owing to ageing populations and changing lifestyles. This continued growth underlines the importance of developing and marketing osteoporosis therapies which can be anabolic, antiresorptive or dual drugs.

Current drugs in the market and the new upcoming osteoporosis drugs currently in development offer a solution for osteoporotic patients, and we expect product demand to increase rapidly in the coming 10 years. The three top leading drugs in 2013 were Forteo, Evista and Prolia. Our study notes that Merck, Amgen and Eli Lilly are set to be leaders in this market over the next ten years with its strong late stage R&D pipeline and expanding sales. Sales for bisphosphonates are expected to decline and the general trend in the osteoporosis drug market will be shifting from antiresorptive drugs to anabolic drugs.

There are few challenges to meet, and the opportunity for growth in this market is vast. Moreover, there will be strong opportunities for the innovative osteoporosis therapies such as Romosozumab and Odanacatib which are expected to become blockbuster drugs shortly after their introduction in the market.”

The report provides revenue forecasts to 2024 for the osteoporosis drug market segmented by therapeutic classes, drug categories and branded drugs. Revenue forecasts for the leading regional markets to 2024 are also provided. The report also provides osteoporosis drug sales forecasts for leading companies such Eli Lilly, Amgen, Merck and GSK. Moreover, individual sales forecasts to 2024 for leading osteoporosis drugs are provided including Forteo, Evista, Prolia, Actonel/Atelvia, Fosamax, Boniva and others.

The analysis for the regional markets is broken down  by countries, showing sales forecasts for the US, Japan, Germany, France, Italy, Spain, UK, China, India, Russia, Brazil and South Korea; as well as by regions, showing forecasts for the EU5 markets, the BRICK Countries and RoW.

Additionally, the report includes a complete strategic analysis of the osteoporosis drug market giving PESTEL analysis, Porter’s 5 Forces Analysis and SWOT analysis. It also includes exclusive interviews with industry experts regarding insightful unmet needs, current market trends and insights for the future.

Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies adds to the extensive range of analytical reports on industries and markets in healthcare.